A study on cost analysis of oral antihypertensive drugs available in India

Avanthi E, A. Rodrigues, Abhishek Achar, Mahesh G K, Anand Koppal
{"title":"A study on cost analysis of oral antihypertensive drugs available in India","authors":"Avanthi E, A. Rodrigues, Abhishek Achar, Mahesh G K, Anand Koppal","doi":"10.18231/j.joapr.2022.14.18","DOIUrl":null,"url":null,"abstract":"The major health care problem in developing world is shifting from communicable diseases to non-communicable disease which causes morbidities more than mortality affecting the personal efficiency. Hypertension is a major health care burden in developing countries like India causing both morbidity and mortality. Few studies shows that the hypertension prevalence has raised from 2% to 15% in rural population and 2% to 25% in urban population in last six decades in India. This research work aims to enumerate the price of commonly available oral antihypertensive drugs in India. It also aims to study the cost variation of oral antihypertensive drugs. The present study was carried out in the department of Pharmacology in a tertiary care medical college in south India. The cost analysis of individual drugs by different manufacturers were done. Percentage of cost variation was analysed. The variation in cost of most of the antihypertensive drugs is more than 100%. It’s found maximum in Amlodipine (5mg) with cost variation of 625%, Atenolol 100 mg with cost variation of 413%. In India there is a wide price variation among antihypertensive drugs. The major gap in the cost variation of antihypertensive drugs to be narrowed for the benefit of the patients. So the government and the prescribing doctors should think about the huge difference in cost and work in the direction of benefitting the patient.","PeriodicalId":15232,"journal":{"name":"Journal of Applied Pharmaceutical Research","volume":"96 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Pharmaceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.joapr.2022.14.18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The major health care problem in developing world is shifting from communicable diseases to non-communicable disease which causes morbidities more than mortality affecting the personal efficiency. Hypertension is a major health care burden in developing countries like India causing both morbidity and mortality. Few studies shows that the hypertension prevalence has raised from 2% to 15% in rural population and 2% to 25% in urban population in last six decades in India. This research work aims to enumerate the price of commonly available oral antihypertensive drugs in India. It also aims to study the cost variation of oral antihypertensive drugs. The present study was carried out in the department of Pharmacology in a tertiary care medical college in south India. The cost analysis of individual drugs by different manufacturers were done. Percentage of cost variation was analysed. The variation in cost of most of the antihypertensive drugs is more than 100%. It’s found maximum in Amlodipine (5mg) with cost variation of 625%, Atenolol 100 mg with cost variation of 413%. In India there is a wide price variation among antihypertensive drugs. The major gap in the cost variation of antihypertensive drugs to be narrowed for the benefit of the patients. So the government and the prescribing doctors should think about the huge difference in cost and work in the direction of benefitting the patient.
印度口服降压药成本分析研究
发展中国家的主要保健问题正在从传染病转向非传染性疾病,后者造成的发病率大于死亡率,影响个人的工作效率。在印度等发展中国家,高血压是一个主要的卫生保健负担,造成发病率和死亡率。很少有研究表明,在过去60年中,印度农村人口的高血压患病率从2%上升到15%,城市人口的高血压患病率从2%上升到25%。本研究工作旨在列举印度常用口服降压药的价格。同时研究口服降压药的成本变化情况。本研究是在印度南部一所三级医疗学院的药学系进行的。对不同厂家生产的单个药品进行了成本分析。分析了成本变动的百分比。大多数降压药的成本差异超过100%。氨氯地平(5mg)的成本变化最大,为625%;阿替洛尔(100mg)的成本变化为413%。在印度,抗高血压药物的价格差异很大。降压药成本变化的主要差距有待缩小,以造福患者。因此,政府和开处方的医生应该考虑到成本上的巨大差异,并朝着有利于患者的方向努力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信